- CRB-601 is a highly potent and selective
anti-αvβ8 integrin monoclonal antibody designed to block
the activation of TGFb in the local tumor
microenvironment
- Additional non-clinical data demonstrates combination
benefit across a diverse range of syngeneic models with
differential sensitivity to checkpoint inhibition
- Anti-tumor activity correlates with increases in
proliferating CD4+ and CD8+ T-cells as well as the NK cell
population and a shift towards M1 macrophage polarization,
supporting the hypothesis the CRB-601 may overcome immune cell
exclusion
NORWOOD,
Mass., May 11, 2022 /PRNewswire/ -- Corbus
Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the
"Company"), an immunology company, announced that new preclinical
data for CRB-601 are being presented today in an oral presentation
at the New York Academy of Sciences (NYAS) Frontiers in Cancer
Immunotherapy Conference in New York,
NY.
The latest preclinical data for CRB-601 demonstrate its
significant effects on inhibiting tumor growth as a single agent
and in combination with anti-PD-1 treatment in the MC38 and EMT6
syngeneic tumor models. In addition, CRB-601 restores an anti-PD-1
effect in the 4T1 syngeneic tumor model, a "cold" immune
cell-depleted tumor model, when added in combination. This data
marks the first time such an effect has been documented in this
model with an anti-αvβ8 agent.
The anti-tumor effects in the immune excluded EMT6 model
correlated with changes in the immune cell populations in the tumor
micro-environment. There were increases in proliferating CD4+ and
CD8+ T-cells, NK cells, and a shift in macrophage polarization to
the inflammatory M1 phenotype. Collectively these data suggest that
treatment with CRB-601 could overcome the immune excluded phenotype
established in this model and enhance the efficacy of treatment
with anti-PD-1 therapy.
Additionally, in a rechallenge model, tumor-bearing mice
initially rendered tumor-free by treatment with CRB-601 + anti-PD-1
were subsequently reinoculated with the same tumor cells (MC38) and
monitored for tumor regrowth. After 30 days no tumors had formed in
this cohort of animals, whereas all the treatment naïve control
mice succumbed to the burden of tumor growth. These data illustrate
that the combination treatment of CRB-601 + anti-PD-1 led to
durable T-cell memory protection.
"CRB-601 demonstrates robust pre-clinical anti-tumor activity
alone and in combination with anti-PD-1 therapy in tumors
exhibiting a range of immune involvement. The ability of CRB-601 to
significantly reduce the growth of tumors that are non-responsive
to checkpoint inhibition and to re-sensitize these tumors to
checkpoint blockade continues to support our hypothesis that
effective blockade of TGFβ should lead to immune cell perfusion and
manifest the benefit of anti-PD-1 therapy. The orchestration of a
response involving both the adaptive and innate arms of the immune
system by CRB-601 is especially compelling," commented Rachael Brake, Ph.D., Chief Scientific Officer
of Corbus.
Corbus is currently developing CRB-601 as a potential treatment
for solid tumor cancers, and the program is advancing toward an IND
submission in the first half of 2023.
The NYAS presentation is available on the Company website at:
corbuspharma.com/NYASpresentation
About Corbus
Corbus is an immunology company committed to connecting
innovation to our purpose of improving lives by developing new
medicines that target the nexus between the immune system and
cancer. Corbus' current pipeline includes anti-integrin monoclonal
antibodies that block activation of TGFβ and small molecules that
activate or inhibit the endocannabinoid system. Corbus is
headquartered in Norwood,
Massachusetts. For more information on Corbus, visit
corbuspharma.com. Connect with us on Twitter, LinkedIn and
Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to the Company's restructuring, trial results, product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of forward-looking
expressions, including, but not limited to, "expect," "anticipate,"
"intend," "plan," "believe," "estimate," "potential," "predict,"
"project," "should," "would" and similar expressions and the
negatives of those terms. These statements relate to future events
or our financial performance and involve known and unknown risks,
uncertainties, and other factors, including the potential impact of
the recent COVID-19 pandemic and the potential impact of sustained
social distancing efforts, on our operations, clinical development
plans and timelines, which may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such factors include those set forth in
the Company's filings with the Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this press release. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Sean.moran@corbuspharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/corbus-presents-latest-preclinical-data-for-crb-601-at-the-new-york-academy-of-sciences-frontiers-in-cancer-immunotherapy-conference-301544859.html
SOURCE Corbus Pharmaceuticals